Latest Conference Articles

Tracy Russell, senior director, State Government Affairs at CoverMyMeds, discusses her presentation at Asembia Summit 2022 on legislation aligned with the movement to expand the pharmacist’s role on the care team.

Regardless of the ability to access and dispense products, pharmacists are responsible for getting patients the best care.

Pharmacists can play a more active role in educating patients on tools and resources available to them, enrolling patients in programs, gathering subjective and objective data.

Ray Tancredi, divisional vice president of Specialty Pharmacy, Development & Brand Rx/Vaccine Purchasing at Walgreens, addresses his presentation on the specialty pharmaceutical pipeline, and specifically what approvals pharmacists should look for on the horizon.

Sonia T. Oskouei, PharmD, vice president of biosimilars at Cardinal Health, discussed how pharmacists can impact biosimilar adoption.

Awards honor excellence and improvement in overall CMS Medicare Star Ratings and PQA Medication Measures.

Jayson Slotnik, JD, MPH, partner at Health Policy Strategies, discusses his hopes for the future of value-based contracting and the ideal model for pharmacy’s involvement.

Patient data are essential to providing coordinator care, but more data also creates heightened risks.

Prescription medications are vital to optimal patient outcomes, but they are also becoming increasingly expensive.

Digital medicine is the use of technology to measure or intervene in certain health conditions and is overseen by the FDA, unlike digital health apps or technologies.

A panel of experts at the Asembia 2022 Specialty Pharmacy Summit discussed some of the obstacles in providing medications approved under Emergency Use Authorization.

Tracy Russell, senior director of State Government Affairs at CoverMyMeds, discusses how the role of the pharmacist in the specialty pharmacy space has expanded during the COVID-19 pandemic.

Stay tuned at PharmacyTimes.com for exclusive session coverage and interviews with experts.

Session highlights novel agents that have recently entered, or will imminently enter, into phase 1 clinical trials.

David DeRemer, PharmD, BCOP, FCCP, FHOPA, a past-president on the board of Hematology/Oncology Pharmacy Association (HOPA), discusses why a greater focus on colorectal cancer screening was important to highlight at the HOPA 2022 annual conference.

David DeRemer, PharmD, BCOP, FCCP, FHOPA, a past-president on the board of Hematology/Oncology Pharmacy Association (HOPA), discusses key takeaways from the HOPA 2022 annual conference.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses how experience as a caregiver can help inform the work of an oncology pharmacist on the clinical care team.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses how oncology pharmacists with experience as a caregiver can utilize those skills while still honoring the boundaries of both themselves and their patients.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the unique struggles that come from being an oncology pharmacist and a caregiver.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses how oncology pharmacists can help their patients overcome some of the barriers patients with cancer may encounter during treatment.

Benyam Muluneh, PharmD, BCOP, CPP, assistant professor at the University of North Carolina Eshelman School of Pharmacy, discusses his presentation at the HOPA 2022 annual conference on the Oral Chemotherapy Collaborative (OCC) and how it works to optimize care for patients taking oral anti-cancer agents.

The investigational selective, covalent, and orally bioavailable KRASG12C¬ inhibitor shows a 57% confirmed overall response rate at the recommended dose of 200 mg twice daily.

Results are from an exploratory analysis of 34 patients who received at least 1 dose after disease progression or suboptimal response with ruxolitinib monotherapy

Results show that 64% of individuals treated with lorlatinib were without disease progression after 3 years compared with about 19% of those treated with crizotinib (Xalkori).

Sotorasib demonstrates clinical benefit and prolonged tumor response seen, with a 40.7% objective response rate.

Britny Brown, PharmD, BCOP, vice chair of the Hematology/Oncology Pharmacy Association (HOPA) DEI Task Force and clinical assistant professor at the University of Rhode Island College of Pharmacy, discusses the role of the task force within HOPA and its impact on the field more broadly.

Peptide-targeted radionuclide therapy FAP-2286 (Clovis Oncology) showed potent affinity for human fibroblast activation protein by biochemical and cell-based assays.

In an interview with Pharmacy Times®, Ryan Haumschild, PharmD, MS, MBA director of pharmacy at Emory Healthcare and Winship Cancer Institute, discusses the pharmacists role in care teams for targeted therapies at the Academy of Managed Care Pharmacy Annual Meeting.